American Journal of Bioethics
May 2, 2024
Edward Jacobs, B. Earp, Paul S. Appelbaum et al.
29 citations
A workshop on psychedelic ethics, the first Hopkins-Oxford Psychedelic Ethics (HOPE) meeting, was held in August 2023 at the University of Oxford to address ethical issues surrounding psychedelics. The organizers (BDE, DBY, EJ) aimed to foster interdisciplinary discussion on topics such as informed consent, therapeutic use, and societal implications. The report outlines the workshop's structure, key themes, and proposed guidelines for ethical research and practice in the field.
The Lancet Child & Adolescent Health
September 2, 2025
Khaleel Rajwani, Edward Jacobs, Lori Bruce et al.
6 citations
No Summary
Philosophical Psychology
September 8, 2025
Mina Caraccio, Katherine Cheung, Sebastian Porsdam Mann et al.
3 citations
As interest in psychedelics like psilocybin, ketamine, and MDMA revives and their legal status changes in many places, ethical guidelines are urgently needed for both medical and non-medical use. This paper argues that focusing only on medical applications neglects potentially valuable uses in other contexts and raises ethical issues including hype, exceptionalism, informed consent, therapeutic touch, data collection, and balancing access with safety. The authors call for renewed attention to the treatment-versus-enhancement distinction from bioethics and stress that guidelines should be flexible and context-sensitive. They recommend incorporating diverse stakeholder perspectives and cross-sector collaboration in future research and policy for psychedelic bioethics.
Journal of Law, Medicine & Ethics
January 1, 2025
Lori Bruce
As psychedelics become more available through legal and underground channels, clinicians lack sufficient knowledge and training to discuss their benefits and harms with patients, creating liability risks that may grow if federal deregulation occurs. Stakeholders should collaborate to expand public and clinical education and develop widely accessible post-trip counseling services for users struggling with ongoing emotional and neuropsychiatric effects, which can sometimes be disabling. Thoughtful collaboration can establish a foundation for psychedelic medicine as a new clinical practice area.